FINWIRES · TerminalLIVE
FINWIRES

$TECH

28 stories mentioning TECHUpdated 30d ago

Every FINWIRES story that references TECH, newest first.

What are analysts saying about TECH?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on TECH?

Wire

Bio-Techne's Fiscal Q4 Organic Revenue Growth Consistent With Progressive Improvement Story, RBC Says

Bio-Techne's (TECH) fiscal Q4 organic revenue growth of 3% is consistent with the progressive improvement story reflected in management's expectation of fiscal 2027 being a roughly 6% sales growth year, RBC Capital Markets said in a Wednesday note.RBC said that this sequential improvement lends credibility to the bridge year thesis and it is reasonable to expect the current organic trajectory to continue building from here. RBC expects fiscal 2027 sales growth of about 5%.Additionally, Bio-Techne's 3% organic growth in the Protein Sciences segment and 8% growth in the Diagnostics & Spatial Biology segment are directionally consistent with industry peers, without standing out as either a positive or negative outlier, according to the note.RBC further said that the Diagnostics & Spatial Biology segment's 8% organic growth adds to the narrative that spatial technology is well positioned for the future of drug development.RBC maintained the company's sector perform rating with a $73 price target.Price: $72.18, Change: $-0.05, Percent Change: -0.07%

$TECH
Research

Wells Fargo Downgrades Bio-Techne to Equalweight From Overweight, Adjusts PT to $73 From $62

Bio-Techne (TECH) has an average rating of hold and mean price target of $70.09, according to analysts polled by FactSet.Price: $72.25, Change: $+0.02, Percent Change: +0.03%

$TECH
Research

RBC Capital Downgrades Bio-Techne to Sector Perform From Outperform, Adjusts Price Target to $73 From $62

Bio-Techne (TECH) has an average rating of hold and mean price target of $70.33, according to analysts polled by FactSet.

$TECH
Research

Benchmark Downgrades Bio-Techne to Hold From Buy

Bio-Techne (TECH) has an average rating of overweight and mean price target of $68.33, according to analysts polled by FactSet.

$TECH
Research

TD Cowen Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $65

Bio-Techne (TECH) has an average rating of overweight and mean price target of $68.33, according to analysts polled by FactSet.

$TECH
Research

Stephens Downgrades Bio-Techne to Equal Weight From Overweight, Adjusts Price Target to $73 From $68

Bio-Techne (TECH) has an average rating of overweight and mean price target of $67.42, according to analysts polled by FactSet.

$TECH
Research

Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Raises Price Target to $73 From $66

Bio-Techne (TECH) has an average rating of overweight and mean price target of $67, according to analysts polled by FactSet.

$TECH
Research

Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $66

Bio-Techne (TECH) has an average rating of overweight and mean price target of $67, according to analysts polled by FactSet.

$TECH
Research

William Blair Downgrades Bio-Techne to Market Perform From Outperform

Bio-Techne (TECH) has an average rating of overweight and mean price target of $67, according to analysts polled by FactSet.

$TECH
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%.The iShares Biotechnology ETF (IBB) advanced 1.3%.In corporate news, Bio-Techne (TECH) shares jumped 20% after the company agreed to be acquired by Germany's Merck in an all-cash deal with an enterprise value of $11.3 billion.Eli Lilly (LLY) shares rose 1% after the company said its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.Kymera Therapeutics (KYMR) shares jumped 16% after the company said it has completed enrollment in a phase 2b trial of KT-621 in moderate to severe atopic dermatitis ahead of schedule.PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating postoperative pain treatment, the company said. The shares climbed 13%.

$KYMR$LLY$PRFX$TECH
Wire

Top Midday Gainers

Kymera Therapeutics (KYMR) has completed enrollment in its phase 2b Broaden2 trial of KT-621 in moderate-to-severe atopic dermatitis ahead of schedule, the company said Thursday.Shares jumped 17% following an increase in intraday trading volume to about 2.7 million from a daily average of about 636,000.WidePoint (WYY) stock surged 14% after the company said it won the Department of Homeland Security's Cellular Wireless Managed Services 3.0 contract.More than 5.4 million shares of the company traded intraday compared with a daily average of about 140,000.Bio-Techne (TECH) signed a definitive agreement to be acquired by Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion, the companies said Thursday.Shares climbed 20% as intraday trading volume catapulted to over 40.7 million from a daily average of about 2.7 million.Price: $116.86, Change: $+16.99, Percent Change: +17.01%

$KYMR$TECH$WYY
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.6%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Bio-Techne (TECH) shares surged nearly 20% after it said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with an enterprise value of about $11.3 billion, as the German drugmaker aims to expand its presence in life sciences markets.Eli Lilly (LLY) shares rose 0.5% after it said Thursday its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday. Its shares jumped 17%.

$LLY$PRFX$TECH
International

Update: US Equity Indexes Mixed as Tech Bulls Whistle Past Micron's Blockbuster Results, Inflation Surges to Three-Year High

(Updates with index/price moves, macroeconomic data, and company/political news from the first paragraph.)US equity indexes traded mixed after strong quarterly results from the $1.4 trillion market-cap Micron Technology (MU) failed to lift technology, and as the annual inflation rate surged to its highest level in more than three years.The Nasdaq Composite fell 0.5% to 25,338.8 after midday Thursday. The S&P 500 slipped by less than 0.1% to 7,354.5, giving up intraday gains. The Dow Jones Industrial Average rose 0.3% to 52,022.6, off session highs. Communication services and consumer discretionary led the decliners, while industrials and health care were standout gainers.In company news, Micron Technology (MU) shares rose nearly 16%, among the top gainers on the S&P 500 and the Nasdaq, after the company reported fiscal Q3 adjusted earnings and revenue that topped estimates, with Q4 guidance also beating consensus. Shares jumped more than 19% earlier in the session.In economic news, annual inflation accelerated to 4.1% in May, the fastest print since April 2023, matching consensus, based on the personal consumption expenditures, or PCE, price index data from the Bureau of Economic Analysis. It follows a 3.8% gain in April. Core PCE inflation, which strips out food and energy, accelerated to 3.4% from a year ago, as expected, from 3.3% in April. That's the highest reading since October 2023.On a month-on-month basis, inflation held steady at 0.4% in May, slower than the 0.5% consensus. Core PCE was unchanged at 0.3%, in line with market expectations."PCE price inflation remains too high and will keep the [Federal Reserve] on hold and mulling a potential rate hike at upcoming meetings," Scott Anderson, chief US economist at BMO, said. "On the bright side, a lot of the goods price inflation seemed to be driven by the energy complex, so as energy prices drop this source of inflation pressure should fade."While the probability of two interest rate increases by December remains elevated, the likelihood slipped to 29% following the PCE data, versus 31% on Wednesday, according to the CME FedWatch tool. There is only a 21% chance that the target rate for fed funds will remain in the 3.5% to 3.75% range by the end of this year.Most US Treasury yields declined, with the 10-year down 1.4 basis points to 4.39%. The two-year rate dropped 2.6 basis points to 4.11%.Gold futures jumped 0.9% to $4,045.20, and silver futures climbed 0.5% to $58.83.Further in economic news, gross domestic product rose by 2.1% in Q1, revised up from a 1.6% jump in the second estimate, above expectations for no revision in a Bloomberg-compiled survey. Sequential economic growth was 0.5% in Q4.In geopolitical news, Iran's Islamic Revolutionary Guard Corps has warned commercial vessels to only use routes through the Strait of Hormuz approved by Tehran, reopening a point of friction in fragile negotiations between the United States and Iran over the future of the strategic waterway, Al Jazeera, a Middle East news broadcaster, reported on Thursday.The warning came after Oman announced a new shipping transit route through the strait on Wednesday, saying it had coordinated the route with the International Maritime Organization as maritime traffic slowly resumes following weeks of disruption, the news report said.Meanwhile, Israel will continue occupying areas of Lebanon, Syria, and Gaza, rejecting pressure to withdraw from territory its military has seized, Israeli Defence Minister Israel Katz was cited as saying in a separate Al Jazeera report.The front-month global benchmark North Sea Brent rose 1.5% to $74.86 per barrel, and the US West Texas Intermediate climbed 1.7% to $71.56 per barrel, rebounding after touching pre-Iran war levels recently.Further in company news, Bio-Techne (TECH) has signed a definitive agreement to be acquired by Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion, the companies said Thursday. Bio-Techne shares soared 20%, the top gainer on the S&P 500.

Dow JonesNasdaq CompositeS&P 500$MU$TECH
Wire

Sector Update: Healthcare

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.6%.The iShares Biotechnology ETF (IBB) advanced 1.3%.In corporate news, Bio-Techne (TECH) shares surged nearly 20% after it said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with an enterprise value of about $11.3 billion, as the German drugmaker aims to expand its presence in life sciences markets.

$TECH
Wire

Top Midday Stories: Micron Shares Soar After Estimate-Topping Earnings Results; Bio-Techne to be Acquired by Merck for $11.3 Billion

The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nasdaq Composite was down, as investors weighed Micron Technology's (MU) latest earnings results as well as new data from the Federal Reserve's preferred inflation measurement.The personal consumption expenditures index increased by 0.4% in May, below the 0.5% gain expected and matching April's level, lifting the year-over-year rate to 4.1% from 3.8%, the Bureau of Economic Analysis said Thursday. The core PCE index, which excludes food and gas prices, increased by 0.3%, matching expectations and April's level.In company news, Micron Technology (MU) reported fiscal Q3 adjusted earnings late Wednesday of $25.11 per diluted share, up from $1.91 a year earlier and above the FactSet consensus analyst estimate of $20.86. Fiscal Q3 revenue was $41.46 billion, up from $9.30 billion a year earlier and above the FactSet consensus of $35.91 billion. For fiscal Q4, the company expects adjusted EPS of $31, plus or minus $1, on revenue of $50 billion, plus or minus $1 billion. Analysts polled by FactSet expect $25.72 and $43.58 billion, respectively. Micron shares were up 12.8% around midday.Bio-Techne (TECH) has signed a definitive agreement to be acquired by Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion, the companies said Thursday. The proposed transaction has received board approval from Merck, and it's expected to close by late 2026 or early 2027, subject to regulatory and shareholder approvals, the companies said. Bio-Techne shares were up 19.8%.Apple (AAPL) raised its prices for a number of its MacBooks and iPads as it passes on higher costs for memory and storage to customers, according to media reports Thursday. The tech giant raised the prices on the MacBook Neo, MacBook Air 512GB and MacBook Pro 1T to $699, $1,299, and $1,999 from $599, $1,099 and $1,699, respectively, the reports said. Apple raised the prices on iPad Air 128GB and iPad Pro Wifi 256GB to $749 and $1,199 from $599 and $999, respectively, according to the reports. Apple shares were down 5.2%.All 32 large banks subject to the Fed's annual stress test have sufficient capital to absorb losses totaling nearly $708 billion and continue lending to businesses and households under hypothetical stressful conditions, the central bank said late Wednesday. JPMorgan Chase (JPM), Goldman Sachs (GS) and Morgan Stanley (MS) all boosted their dividends shortly after the results were announced. JPMorgan plans to increase its quarterly dividend to $1.65 per share from $1.50 for Q3, and it also authorized a new $50 billion share buyback program, effective July 1. Goldman plans to increase its common dividend to $5 per share from $4.50, beginning July 1. Morgan Stanley plans to raise its quarterly dividend to $1.15 per share from $1.00, expected to be declared in Q3. The bank also reauthorized up to $20 billion of a multi-year common equity share buyback program without an expiry date.Separately, JPMorgan said Thursday that Doug Petno and Troy Rohrbaugh have been named co-presidents of the company, effective immediately. Petno will also now be sole CEO of the company's Commercial & Investment Bank, while Rohrbaugh will be the CEO of Consumer and Community Banking, or CCB. Current CCB CEO Marianne Lake has decided to retire, the company said. Shares of JPMorgan, Goldman and Morgan Stanley were up 2.2%, 1.5% and 2.3%, respectively.Price: $1182.13, Change: $+134.21, Percent Change: +12.81%

$AAPL$GS$JPM$MS$MU$TECH
Research

Leerink Downgrades Bio-Techne to Market Perform From Outperform, Price Target is $73

Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.Price: $70.50, Change: $+11.62, Percent Change: +19.74%

$TECH
Sectors

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

Healthcare stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) retreating by 0.2% and the iShares Biotechnology ETF (IBB) advancing 0.1%.Bio-Techne (TECH) stock rose more than 20% premarket after the company signed a definitive agreement to be acquired by Germany's Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion.RadNet's (RDNT) shares were down 1.8% pre-bell after rising 3.5% at the prior close. The company's DeepHealth unit said it received FDA 510(k) clearance for two breast imaging AI tools, including a breast arterial calcification assessment and prior exam integration for its ProFound Pro platform.Taysha Gene Therapies (TSHA) stock lost more than 9% after the company priced an underwritten public offering of 32.5 million shares at $6.00 each and pre-funded warrants to purchase 833,333 shares at $5.999 each.

$IBB$RDNT$TECH$TSHA$XLV
Bio-Techne to Be Acquired by Germany's Merck in $11.3 Billion Deal
US Markets

Bio-Techne to Be Acquired by Germany's Merck in $11.3 Billion Deal

Bio-Techne (TECH) said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with an enterprise value of about $11.3 billion, as the German drugmaker aims to expand its presence in life sciences markets.Merck KGaA will pay $73 per Bio-Techne share in cash, representing a 36% premium to the US-based company's one-month volume-weighted average trading price, according to a joint statement.Life sciences company Bio-Techne's portfolio includes lab reagents and tools used in biological research, diagnostics and drug development. Merck KGaA said the acquisition would strengthen its position in high-growth life sciences markets, including multi-omics, spatial biology, precision diagnostics and cell and gene therapy.The acquisition would give Merck KGaA access to ProteinSimple, automated protein detection and analysis systems, strengthening its analytical and bioprocessing capabilities, the statement said. It would also expand Merck's spatial biology and diagnostics tools through Bio-Techne's RNAscope technology.Bio-Techne's shares rose 20% in the most recent premarket activity."This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda," Merck KGaA Chief Executive Kai Beckmann said, adding that the combination will expand the company's scientific capabilities and customer reach while accelerating innovation.Merck KGaA expects the proposed deal to be immediately accretive to sales growth and EBITDA pre margin after closing, and accretive to earnings per share by year three after closing.The deal is expected to close in late 2026 or early 2027, subject to Bio-Techne shareholder approval and regulatory clearances.Bio-Techne will have expanded scale and capabilities to accelerate innovation as part of Merck KGaA, CEO Kim Kelderman said.

$TECH
Research

Evercore ISI Upgrades Bio-Techne to Outperform From In Line, Adjusts Price Target to $73 From $50

Bio-Techne (TECH) has an average rating of overweight and mean price target of $65.33, according to analysts polled by FactSet.

$TECH
Sectors

Sector Update: Healthcare

Healthcare stocks were flat to lower premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) retreating by 0.3% and the iShares Biotechnology ETF (IBB) flat.Bio-Techne (TECH) stock rose more than 19% premarket after the company signed a definitive agreement to be acquired by Germany's Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion.

$IBB$TECH$XLV

Showing 1-20 of 28

Track with the FINWIRES app suite